Genmab A/S (CPH:GMAB)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Denmark Revenue	3.33B	2.87B
Denmark Revenue Growth	15.97%	23.14%
Netherlands Revenue	1.00M	-
United States Revenue	180.00M	131.00M
United States Revenue Growth	37.41%	138.18%
Japan Revenue	213.00M	122.00M
Japan Revenue Growth	74.59%	1933.33%
Revenue (Total)	3.72B	3.12B
Revenue (Total) Growth	19.19%	30.59%

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
DARZALEX Royalties Revenue	2.44B	2.02B
DARZALEX Royalties Revenue Growth	21.00%	23.49%
Kesimpta Royalties Revenue	443.00M	323.00M
Kesimpta Royalties Revenue Growth	37.15%	48.85%
TEPEZZA Royalties Revenue	105.00M	106.00M
TEPEZZA Royalties Revenue Growth	-0.94%	3.92%
Other Product Royalties Revenue	111.00M	69.00M
Other Product Royalties Revenue Growth	60.87%	97.14%
Total Royalties Revenue	3.10B	2.52B
Total Royalties Revenue Growth	23.24%	26.55%
Net Product Sales	398.00M	253.00M
Net Product Sales Growth	57.31%	314.75%
Reimbursement Revenue	53.00M	144.00M
Reimbursement Revenue Growth	-63.19%	16.13%
Milestone Revenue	97.00M	145.00M
Milestone Revenue Growth	-33.10%	-15.20%
Collaboration Revenue	70.00M	62.00M
Collaboration Revenue Growth	12.90%	37.78%
Revenue (Other)	-3.10B	-2.52B
Revenue (Total)	3.72B	3.12B
Revenue (Total) Growth	19.19%	30.59%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
J&J Revenue	2.57B	2.09B
J&J Revenue Growth	22.67%	20.59%
AbbVie Revenue	66.00M	58.00M
AbbVie Revenue Growth	13.79%	-45.28%
Roche Revenue	106.00M	107.00M
Roche Revenue Growth	-0.94%	4.90%
Novartis Revenue	446.00M	408.00M
Novartis Revenue Growth	9.31%	86.30%
BioNTech Revenue	40.00M	127.00M
BioNTech Revenue Growth	-68.50%	11.40%
Pfizer Revenue	77.00M	77.00M
Pfizer Revenue Growth	-	42.59%
Other Collaboration Partner Revenue	22.00M	-
Revenue (Total)	3.72B	3.12B
Revenue (Total) Growth	19.19%	30.59%

Data Source: Fiscal.ai Last updated: Mar 31, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 28, 2026

Data Sources Report a data error